Mr. Grant Larsen reports

SOLARVEST CONTINUES RESEARCH & DEVELOPMENT IN PEI AND ADDS DIRECTOR

The buyer of Solarvest Bioenergy Inc.'s property located at 3867 Greenfield Rd., Summerville, PEI, upon successful closing of the sale, has agreed to lease space to the company that the company may continue research and development of its products and technology.

In addition, the company intends to introduce its organic omega-3 products in the United States. Initially, the company will focus on marketing its dried powder currently in inventory in Germany followed by the introduction and marketing of the capsule. The company will review its options to commercialize its products and will actively pursue partnerships in the U.S. to assist with the development of its organic omega-3 products.

The company further plans to review its bone morphogenetic protein technology. In 2015, Solarvest announced its patented algal platform to efficiently produce complex bioactive therapeutic compounds:

• Microalgae harbour no known human pathogens, unlike the currently utilized human, bacterial and animal cells lines.
• Algae are capable of high-quality, volume production of active proteins.
• Algae can be grown in sterile bioreactors under controlled conditions.

Solarvest's algal platform has many advantages as compared with current industry processes, which utilize E. coli or yeast in the production and can cost millions of dollars per gram of bioactive compound. The company's algal platform breakthrough could substantially reduce the cost of production, with the potential to increase the economical access to hundreds of products for human and animal health.

Previously, a proof-of-concept study required Solarvest's algal platform to produce BMP and was completed using experts at the University of Prince Edward Island. The goal of the study was to determine if the algae-produced protein would be active and induce osteogenesis in undifferentiated stem cells. The successful result, in conjunction with previous positive results with other complex proteins, confirms that Solarvest's algal platform is capable of producing active recombinant proteins. In the case of human recombinant BMP proteins, Solarvest produced a complex, soluble, properly folded and dimerized protein. A dimer is two individual protein units joined together, and BMP is only active when presented as a dimer with the proper 3-D configuration.

Solarvest intends to continue with BMP proof of concept and explore avenues to commercialize BMP for veterinary and human applications, and will seek supportive partnerships with companies that are active in this and other bioactive protein markets.

The company is also pleased to announce that Paul Lipoth, a long-term shareholder of the company, has joined the board, effective immediately. Mr. Lipoth brings years of experience in doing business with TSX Venture companies and will assist with guiding Solarvest through its next phase of development.

A review of the company's patents is currently under way, and a revised business plan is being worked on. This board and management team are committed to creating value for shareholders. The company will provide further updates as they become available.

About Solarvest Bioenergy Inc.

Solarvest is a Canadian algal biologic research company with several unique patents in organic ingredient production with global commercial product applications. With a commitment to innovation and a dedication to harnessing the power of nature, Solarvest is poised to transform the landscape of health care with its proprietary organic solutions.

We seek Safe Harbor.